S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
NASDAQ:ALT

Altimmune (ALT) Stock Price, News & Analysis

$10.29
+1.40 (+15.75%)
(As of 03:24 PM ET)
Today's Range
$8.84
$10.50
50-Day Range
$8.22
$13.81
52-Week Range
$2.09
$14.84
Volume
6.58 million shs
Average Volume
6.03 million shs
Market Capitalization
$552.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.75

Altimmune MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
53.2% Upside
$15.75 Price Target
Short Interest
Bearish
23.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.12mentions of Altimmune in the last 14 days
Based on 22 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.43) to ($1.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.33 out of 5 stars

Medical Sector

759th out of 938 stocks

Pharmaceutical Preparations Industry

351st out of 433 stocks

ALT stock logo

About Altimmune Stock (NASDAQ:ALT)

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

ALT Stock Price History

ALT Stock News Headlines

7 Stocks That Will Drive the Weight Loss Drugs Market (ALT)
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Q4 2023 Altimmune Inc Earnings Call
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
ALT Stock Earnings: Altimmune Beats EPS for Q4 2023
Here's what Wall Street expects from Altimmune's earnings report
(ALT) - Analyzing Altimmune's Short Interest
Altimmune (NASDAQ: ALT)
UroGen Pharma Q4 2023 Earnings Preview
See More Headlines
Receive ALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALT
Employees
52
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.75
High Stock Price Target
$20.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+52.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-84,710,000.00
Pretax Margin
-28,124.01%

Debt

Sales & Book Value

Annual Sales
$4.41 million
Book Value
$3.77 per share

Miscellaneous

Free Float
51,526,000
Market Cap
$553.96 million
Optionable
Optionable
Beta
0.08
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Vipin K. Garg Ph.D. (Age 66)
    President, CEO & Director
    Comp: $916.16k
  • Mr. Richard I. Eisenstadt M.B.A. (Age 66)
    Chief Financial Officer
    Comp: $619.69k
  • Dr. M. Scot Roberts Ph.D. (Age 65)
    Chief Scientific Officer
    Comp: $599.25k
  • Dr. Matthew Scott Harris AGAF (Age 71)
    FCAP, M.D., MS, Chief Medical Officer
    Comp: $643.04k
  • Mr. Bertrand Georges Ph.D.
    Chief Technology Officer
  • Mr. Tony Blandin B.S.
    Vice President of Quality & Compliance Management
  • Mr. Raymond M. Jordt M.B.A. (Age 51)
    Chief Business Officer
  • Mr. Andrew Shutterly M.S.
    Corporate Controller

ALT Stock Analysis - Frequently Asked Questions

Should I buy or sell Altimmune stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALT shares.
View ALT analyst ratings
or view top-rated stocks.

What is Altimmune's stock price target for 2024?

4 brokerages have issued 1-year price objectives for Altimmune's shares. Their ALT share price targets range from $13.00 to $20.00. On average, they anticipate the company's share price to reach $15.75 in the next twelve months. This suggests a possible upside of 53.2% from the stock's current price.
View analysts price targets for ALT
or view top-rated stocks among Wall Street analysts.

How have ALT shares performed in 2024?

Altimmune's stock was trading at $11.25 at the beginning of the year. Since then, ALT stock has decreased by 8.6% and is now trading at $10.28.
View the best growth stocks for 2024 here
.

Are investors shorting Altimmune?

Altimmune saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 12,510,000 shares, an increase of 15.7% from the February 29th total of 10,810,000 shares. Based on an average daily trading volume, of 6,610,000 shares, the days-to-cover ratio is currently 1.9 days.
View Altimmune's Short Interest
.

When is Altimmune's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ALT earnings forecast
.

How were Altimmune's earnings last quarter?

Altimmune, Inc. (NASDAQ:ALT) issued its earnings results on Monday, November, 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.45. The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.11 million. During the same period in the previous year, the business posted ($0.54) EPS.

When did Altimmune's stock split?

Shares of Altimmune reverse split on the morning of Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Altimmune own?
Who are Altimmune's major shareholders?

Altimmune's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.65%), Vanguard Group Inc. (6.65%), Nuveen Asset Management LLC (3.21%), Point72 Asset Management L.P. (2.32%), Timelo Investment Management Inc. (1.51%) and Goldman Sachs Group Inc. (0.98%). Insiders that own company stock include David Drutz, Diane Jorkasky, M Scot Roberts, Matthew Scott Harris, Vipin K Garg and Wayne Pisano.
View institutional ownership trends
.

How do I buy shares of Altimmune?

Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners